Amendments to the Specification:

Page 6, please replace paragraph 5 with the following amended paragrah:

Fig 3 is a graph showing an elution pattern of Lys-LBS-I in ~~immunoaffinity~~ affinity chromatography using heparin as a ligand.

Pages 6 and 7, please replace paragraph spanning the bottom of page 6 and the top of page 7 with the following amended paragraph:

Fig. 4 is a graph showing an elution pattern of Glu-LBS-I ~~immunoaffinity~~ affinity chromatography using heparin as a ligand.

Page 19, please replace paragraph 2 with the following amended paragraph:

Glu-LBS-I and Lys-LBS-I prepared in Example 4 were passed through ~~immunoaffinity~~ affinity chromatography Hi trap Heparin (trade name) (manufactured by Pharmacia) with heparin as a ligand. A concentration gradient elution based on a salt concentration was carried out to give heparin-binding fractions and proteins contained therein were monitored through absorbance for their heparin-affinity amount.

Pages 19 and 20, please replace the paragraph spanning the bottom of page 19 and the top of page 20 with the following amended paragraph:

Specifically, an ~~immunoaffinity~~ affinity resin (1 ml) equilibrated with Tris buffer (pH 7.2) containing 50 mM NaCl was contacted with each 100 µl of Glu-LBS-I (1 mg/ml) and Lys-LBS-I (1 mg/ml) dissolved in the same buffer and washed with the same buffer 10 ml at a flow rate of 0.5 ml/min. Then, gradient elution was carried out with 50 mM NaCl/Tris 10 ml, 1 M NaCl/Tris buffer (pH 7.2) 10 ml.

Page 20, please replace paragraph 2 with the following amended paragraph:

The results of heparin affinity chromatography are shown in Figs 3 and 4. As shown in Fig. 3, Lys-LBS-I gave fractions with no heparin binding activity, fractions with a moderate heparin binding activity and fractions with a high heparin binding activity whereas Glu-LBS-I gave no fractions with a high heparin binding activity (Fig. 4). The fractions with a high heparin binding activity were subjected to 12.5% SDS-PAGE to prove that the protein contained therein had a molecular weight of around 38 kda, which is consistent with that of LBS-I with no glycosylation (Fig. 5). The starting plasminogen did not dissolve in the above buffer for equilibrium and hence the ~~immunoaffinity~~ affinity chromatography could not be done.

Pages 20 and 21, please replace the paragraph spanning the bottom of page 22 and the top of page 21 with the following amended paragraph:

For Lys-LBS-I prepared in Example 4, ~~immunoaffinity~~ affinity chromatography (Hi trap Heparin; manufactured by Pharmacia) with heparin as a ligand was carried out at a physiological saline at pH ranging from 5.0 to 7.2 to investigate the heparin binding activity. Specifically, the above ~~immunoaffinity~~ affinity resin (1 ml) equilibrated with a citrate buffer (ph 5.0 to 7.2) containing 150 mM NaCl was contacted at 100 µl of Lys-LBS-I (1 mg/ml) dissolved in the same buffer and washed with the same buffer 10 ml at a flow rate of 0.5 ml/min, which was then eluted with 1 M NaCl/citrate buffer (pH 5.0 to 7.2) 10 ml.

Pages 22 and 23, please replace the paragraph spanning the bottom of page 22 and the top of page 23 with the following revised paragraph:

100 µl of Lewis lung cancer 10^7 cells/ml was subcutaneously grafted to 30 male mice (C57BL6/J) of 6 weeks old at the back and the animals were bred for 15 to 18 days. Thereafter, the primary focus formed was surgically removed and the section was sutured. Taking body weight and weight of the primary focus into consideration, mice were ~~dived~~ divided into three groups and bred for 14 days. Mice in each group

received intraperitoneal administration of each 0.5 mg/kg of either Lys-LBS-I or Glu-LBS-I prepared in Example 4 or 100 μl of physiological saline as a control everyday for 10 days. After administration, lungs were removed from mice and their weights were compared. The data were statistically analyzed using non-parametric analysis. Fig. 7 shows effects of Lys-LBS-I and Glu-LBS-I on tumor metastasis and growth. The lungs weighed 0.705 $\pm$ 0.411 g in the control group (physiological saline) whereas they weighed 0.247 $\pm$ 0.05 g in the Lys-LBS-I group to prove that Lys-LBS-I significantly inhibited tumor metastasis and growth. On the other hand, the lungs weighed 0.406 $\pm$ 0.186 g in the Glu-LBS-I group with no significant difference.